Inuvair Nexthaler (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Beclometasone dipropionate is a synthetic corticosteroid that binds to glucocorticoid receptors inside airway cells. This binding alters gene transcription, leading to decreased production of inflammatory cytokines, reduced airway edema, and inhibition of immune cell activation, thereby lowering airway inflammation and hyper‑responsiveness.

The prescribed dose of Inuvair Nexthaler is determined by the treating physician based on the severity of the patient’s asthma or COPD and their response to therapy. Typically, the inhaler is used twice daily, but the exact number of inhalations per dose must follow the clinician’s instructions.

Safety data for beclometasone/formoterol use in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss potential risks with the patient.

To order Inuvair Nexthaler, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Inuvair Nexthaler contains beclometasone dipropionate and formoterol, offering a potent corticosteroid with a rapid‑onset, long‑acting β2‑agonist. Compared with alternatives such as budesonide/formoterol or fluticasone/salmeterol, beclometasone provides comparable anti‑inflammatory efficacy, while formoterol’s fast onset may give quicker symptom relief. Choice among products often depends on patient preference, device handling, and individual response.

Inuvair Nexthaler should be stored at room temperature below 25 °C, protected from moisture and direct sunlight. Keep the device in its original packaging until use. Do not expose the inhaler to extreme temperatures or humidity, as this may affect powder flow and dose consistency.

To use Inuvair Nexthaler, the patient should first exhale fully, then place the mouthpiece between the lips, seal tightly, and inhale sharply and deeply through the device. After inhalation, hold the breath for about 10 seconds before exhaling slowly. The inhaler is typically primed according to the manufacturer’s instructions before the first use.

Serious adverse events, although rare, include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis or angioedema, adrenal suppression with prolonged high‑dose use, cardiac arrhythmias, and opportunistic infections like pneumonia. Patients should be instructed to seek immediate medical attention if they experience sudden worsening of breathing, swelling of the face or throat, or unexplained heart palpitations.

Inuvair Nexthaler is contraindicated in individuals with a known hypersensitivity to beclometasone dipropionate, formoterol fumarate, or any component of the inhaler device. It should also be avoided in patients who have experienced a severe allergic reaction to other inhaled corticosteroids or long‑acting β2‑agonists. Caution is advised for patients with uncontrolled cardiovascular disease, cardiac arrhythmias, or severe hypertension.